Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

April 1, 2026

Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 31, 2026

Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
March 10, 2026

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
March 3, 2026

Immunic to Participate in Investor Conferences in March
February 26, 2026

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

Show per page